Carsgen Therapeutics Holdings Limited (2171)
HKEX HKEX Primary 
OTC PINK Summary
Carsgen Therapeutics Holdings Limited (2171) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Carsgen Therapeutics Holdings Limited ever had a stock split?
Carsgen Therapeutics Holdings Limited Profile
| Biotechnology Industry | Healthcare Sector | Dr. Zonghai Li M.D., Ph.D. CEO | HKEX Exchange | KYG1996C1006 ISIN |
| China Country | 371 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CARsgen Therapeutics Holdings Limited operates as an investment holding company primarily focused on the research, development, and commercialization of innovative chimeric antigen receptor T (CAR-T) cell therapies. With a strong presence in both China and the U.S., the company is at the forefront of developing autologous CAR-T product candidates aimed at treating various cancers. Founded in 2014 and based in Shanghai, China, CARsgen Therapeutics is committed to advancing the field of cancer treatment through its pioneering efforts in CAR-T therapy.
Products and Services
CT053 - An autologous CAR-T therapy targeting B-cell maturation antigen, currently in a pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma.
CT041 - Targets Claudin 18.2 and is under Phase II/III clinical trial for gastric/gastroesophageal junction cancer and Phase I for pancreatic cancer. It is also in Phase I clinical trial for treating gastric or pancreatic cancer.
CT011 - This candidate is in Phase I clinical trial aimed at patients with Glypican-3 positive advanced hepatocellular carcinoma.
CT032 - Targets CD19 and is in Phase I/II clinical trial for addressing B cell non-Hodgkin's lymphoma.
CT0180 and CT0181 - Both target Glypican-3 and are in Phase I clinical trial for patients with Glypican-3 positive hepatocellular carcinoma.
CT0590 - Currently in the pre-clinical stage, this CAR-T therapy targets B-cell maturation antigen for the potential treatment of relapsed/refractory multiple myeloma.
CT048 - Another pre-clinical stage candidate, targeting Claudin 18.2 for possible treatment against gastric/gastroesophageal junction and pancreatic cancer.
KJ-C2112 - A pre-clinical candidate for treating glioblastoma. It targets epidermal growth factor receptor/variant III of the epidermal growth factor receptor.
KJC2113 and KJ-C2114 - Both in pre-clinical stages, these therapies target mesothelin, focusing on the treatment of solid tumors.
AB011 - This candidate is in Phase I clinical trial, targeting gastric/pancreatic cancer for potential treatment.
